Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy.

Farhad Ravandi, M.D., Jorge Cortes, MD, Stefan Faderl, MD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD, Marcos de Lima, MD, Sherry Pierce, RN, Mark Brandt, Gautam Borthakur, MD, Alessandra Ferrajoli, MD., William G. Wierda, M.D., Ph.D, Charles A Koller, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 1038.

https://doi.org/10.1182/blood.V114.22.1038.1038

Published: 2009

Journal Articles

Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL).

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Charles A Koller, MD, Samuel Dara, Rebecca Garris, Partow Kebriaei, MD, Richard Champlin, MD, Gautam Borthakur, MD, William G. Wierda, M.D., Ph.D, Jan A. Burger, MD, PhD, Jorge Cortes, MD, Susan O'Brien

Blood (2009) 114 (22): 837.

https://doi.org/10.1182/blood.V114.22.837.837

Published: 2009

Journal Articles

Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL)

Stefan Faderl, Deborah A. Thomas, Charles A. Koller, Farhad Ravandi, Jan Burger, Susan O’Brien, Samuel Dara, Hagop M. Kantarjian

Blood (2008) 112 (11): 3960.

https://doi.org/10.1182/blood.V112.11.3960.3960

Published: 2008

Journal Articles

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, William G. Wierda, M.D., Ph.D, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Jorge Cortes, MD, Charles A. Koller, MD, Gautam Borthakur, MBBS, Zeev Estrov, Marina Konopleva, MD, PhD, Farhad Ravandi, MBBS, Guillermo Garcia- Manero, MD, Susan O’Brien, M.D.

Blood (2008) 112 (11): 1931.

https://doi.org/10.1182/blood.V112.11.1931.1931

Published: 2008

Journal Articles

Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML).

Stefan Faderl, Gautam Borthakur, Farhad Ravandi, Xuelin Huang, Miloslav Beran, Alessandra Ferrajoli, Charles A. Koller, Deborah A. Thomas, Srdan Verstovsek, Monica Kwari, Hagop M. Kantarjian

Blood (2008) 112 (11): 964.

https://doi.org/10.1182/blood.V112.11.964.964

Published: 2008

Journal Articles

Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.

Fabio P.S. Santos, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Charles A. Koller, MD, Miloslav Beran, MD, PhD, Gautam Borthakur, MD, Carlos Bueso-Ramos, MD, PhD, Michael Keating, MB, BS, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2008) 112 (11): 925.

https://doi.org/10.1182/blood.V112.11.925.925

Published: 2008

Journal Articles

Change in Liver Iron Concentration (LIC), Serum Ferritin (SF) and Labile Plasma Iron (LPI) Over 1 Year of Deferasirox (DFX/Exjade ® ) Therapy in a Cohort of Myelodysplastic Patients

Peter L Greenberg, Charles Schiffer, Charles A Koller, Tara Glynos, Carole Paley

Blood (2008) 112 (11): 5083.

https://doi.org/10.1182/blood.V112.11.5083.5083

Published: 2008

Journal Articles

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Stefan Faderl, MD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Miloslav Beran, MD PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD PhD, Gautam Borthakur, MD, Michael Andreeff, MD PhD, Steve Kornblau, MD, Susan O’Brien, MD, Khanh Vu, MD, Monica Kwari, RN, Jennie Bretz, RN, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 4324.

https://doi.org/10.1182/blood.V110.11.4324.4324

Published: 2007

Journal Articles

Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

John Delmonte, Jr., MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Farhad Ravandi, MD, Srdan Verstovsek, MD/PhD, Susan O’Brien, MD, Charles A. Koller, MD, Stefan Faderl, MD, Deborah A. Thomas, MD, John J. Wright, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 441.

https://doi.org/10.1182/blood.V110.11.441.441

Published: 2007

Journal Articles

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Elias Jabbour, MD, Hagop Kantarjian, M.D., Charles A. Koller, M.D., Stefan Faderl, M.D., Alessandra Ferrajoli, M.D., Mary Ann Richie, R.N., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Zeev Estrov, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.

Blood (2006) 108 (11): 3636.

https://doi.org/10.1182/blood.V108.11.3636.3636

Published: 2006

Journal Articles

Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.

Farhad Ravandi-Kashani, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Miloslav Beran, MD, Sherry Pierce, RN, Charles A. Koller, MD, Jorge Cortes, MD, Stefan Faderl, MD, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 4830.

https://doi.org/10.1182/blood.V108.11.4830.4830

Published: 2006

Journal Articles

Eradication of minimal residual disease in hairy cell leukemia

Farhad Ravandi, Jeffrey L. Jorgensen, Susan M. O'Brien, Srdan Verstovsek, Charles A. Koller, Stefan Faderl, Francis J. Giles, Alessandra Ferrajoli, William G. Wierda, Shirley Odinga, Xuelin Huang, Deborah A. Thomas, Emil J. Freireich, Dan Jones, Michael J. Keating, Hagop M. Kantarjian

Blood (2006) 107 (12): 4658–4662.

https://doi.org/10.1182/blood-2005-11-4590

Published: 2006

Journal Articles

Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.

Stefan Faderl, MD, Deborah A. Thomas, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Miloslav Beran, MD, PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, MD, Michael Andreeff, MD, PhD, Steve Kornblau, MD, Khanh Vu, MD, Rita Jarmon, R.N., Hagop M. Kantarjian, MD

Blood (2005) 106 (11): 1840.

https://doi.org/10.1182/blood.V106.11.1840.1840

Published: 2005

Journal Articles

Increased Bone Marrow Erythroid Precursors Is Associated with Shorter Survival in Low-Grade Myelodysplastic Syndromes.

Hesham M. Amin, MD, MSc, Sherry A. Pierce, RN, Hagop M. Kantarjian, MD, Michael J. Keating, MD, Emil J. Freireich, MD, Charles A. Koller, MD, Miloslav Beran, MD, PhD, Maher Albitar, MD, Susan M. O’Brien, MD, Elihu H. Estey, MD

Blood (2004) 104 (11): 2371.

https://doi.org/10.1182/blood.V104.11.2371.2371

Published: 2004

Journal Articles

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia

Alessandra Ferrajoli, Michael J. Keating, Taghi Manshouri, Francis J. Giles, Amanda Dey, Zeev Estrov, Charles A. Koller, Razelle Kurzrock, Deborah A. Thomas, Stefan Faderl, Susan Lerner, Susan O'Brien, Maher Albitar

Blood (2002) 100 (4): 1215–1219.

https://doi.org/10.1182/blood.V100.4.1215.h81602001215_1215_1219

Published: 2002

NARROW

Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy.

Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL).

Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL)

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML).

Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.

Change in Liver Iron Concentration (LIC), Serum Ferritin (SF) and Labile Plasma Iron (LPI) Over 1 Year of Deferasirox (DFX/Exjade ® ) Therapy in a Cohort of Myelodysplastic Patients

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.

Eradication of minimal residual disease in hairy cell leukemia

Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.

Increased Bone Marrow Erythroid Precursors Is Associated with Shorter Survival in Low-Grade Myelodysplastic Syndromes.

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only